

'Patient perspective'



Session 3: Fundamental challenges in small populations

Correct evidence: The role of randomization and observational data

Elizabeth Vroom
Asterix Conference | Zaandam | 18-19 September 2017



Hopes, concerns and requirements

'Towards optimal trial design which can lead to reliable outcomes and conclusions'

Challenges




1 In 5000 newborn boys (16 diagnosed /yr in NL)

7000 different mutations

Progressive disease

Differences in Natural History

Differences in SoC




Randomisation

Age or stage?

Mutation?

Country? (SoC and nutrition)

Depending on outcome measure



Observational

Evidence is considered 'low'

Market Authorisation and HTA

Use of natural history controls is limited





Natural History controls (registries)

Useful when drug effect is 'big'

Lack of placebo effect

Sharing data of placebo groups from other trials

Natural history data are fast 'outdated'

Thank you!

